Not much heard about these trials these days and when they will conclude and move to the approval stage.
The aHUS Iptacopan ( the pill) trial for adults ( APPELHUS) is due to conclude in August this year according to Novartis’ recent update.
Another Iptacopan trial for switching from existing complement inhibitors to Iptacopan is now recruiting and is expected to be concluded by 2029.
One further Iptacopan trial which is a long term extension for those who participated in the APPELHUS Phase 3 trial is recruiting and will conclude in 2032.
The two Crovalimab ( the injection) trials are now completed ( adults in October 2025 and children in July 2025). As far as is known there is no application to FDA as yet for a marketing licence for use as an aHUS treatment. It has been approved for PNH use.
Indeed is there any interest in entering the aHUS market?
Article No 787
